Results 11 to 20 of about 34,440,044 (184)

Small-molecule agonists for the glucagon-like peptide 1 receptor [PDF]

Proceedings of the National Academy of Sciences, 2007
The peptide hormone glucagon-like peptide (GLP)-1 has important actions resulting in glucose lowering along with weight loss in patients with type 2 diabetes. As a peptide hormone, GLP-1 has to be administered by injection. Only a few small-molecule agonists to peptide hormone receptors have been described and none in the B family of the G protein ...
Knudsen, Lotte Bjerre, Kiel, Dan, Teng, Min, Behrens, Carsten, Bhumralkar, Dilip, Kodra, János T, Holst, Jens Juul, Jeppesen, Claus B, Johnson, Michael D, de Jong, Johannes Cornelis, Jorgensen, Anker Steen, Kercher, Tim, Kostrowicki, Jarek, Madsen, Peter, Olesen, Preben H, Petersen, Jacob S, Poulsen, Fritz, Sidelmann, Ulla G, Sturis, Jeppe, Truesdale, Larry, May, John, Lau, Jesper   +21 more
openaire   +4 more sources

A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia [PDF]

Journal of Anesthesia, Analgesia and Critical Care
Glucagon-like peptide-1 receptor agonists are a class of drugs that mimic a natural incretin hormone released by the intestine after meals, and they are well-suited for treating type 2 diabetes.
Luigi Vetrugno, Cristian Deana, Andrea Da Porto, Enrico Boero, Valentina Bellini, Daniele Guerino Biasucci, Elena Giovanna Bignami   +6 more
doaj   +3 more sources

Glucagon-like Peptide-1 Receptor Agonists and Risk of Tuberculosis in Type 2 Diabetes [PDF]

Nature Communications
Tuberculosis remains a leading cause of illness and death worldwide, and individuals with type 2 diabetes have an increased risk of developing this infection. However, whether different glucose-lowering medications influence this risk is unclear. Here we
Kuang-Ming Liao, Jheng-Yan Wu, Chih-Cheng Lai   +2 more
doaj   +2 more sources

The binding and activation of the glucagon-like peptide-1 receptor by exendin-4 [PDF]

, 2010
Background and purpose Exendin-4 (EX4) has the same physiological properties as glucagon-like peptide-1 (7-36)amide (GLP-1). EX4 has 50% identity with GLP-1, with an extra nine amino acids at its C-terminus.
Nasr, Elsayed Mohammed Nasr
core   +6 more sources

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis [PDF]

, 2012
Background Type 2 diabetes is a risk factor for Alzheimer's disease (AD), most likely linked to an impairment of insulin signalling in the brain. Therefore, drugs that enhance insulin signalling may have therapeutic potential for AD. Liraglutide (Victoza)
Hunter, Kerry, Holscher, Christian
core   +5 more sources

Glucagon-like peptide-1 receptor imaging for localization of insulinomas [PDF]

, 2009
The surgical removal of insulinomas is hampered by difficulties to localize it using conventional radiological procedures. Recently these tumors were shown to exhibit a very high density of glucagon-like peptide-1 receptors (GLP-1R) in vitro that may be ...
Clerici, Thomas, Forrer, Flavio, Gloor, Beat, Reubi, Jean Claude, Rahel Sahli, Mäcke, Helmut R., Brändle, Michael, Beat Gloor, Martius, Ferdinand, Damian Wild, Reubi, Jean-Claude, Thomas Clerici, Flavio Forrer, Maecke, Helmut, Wild, Damian, Emanuel Christ, Ferdinand Martius, Christ, Emanuel, Sahli, Rahel, Jean Claude Reubi, Michael Brändle, Helmut Maecke   +21 more
core   +3 more sources

Glucagon-like peptide analogues for type 2 diabetes mellitus : systematic review and meta-analysis [PDF]

, 2010
Background Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis ...
Deepson S Shyangdan, Christine Clar, Pawana Sharma, Royle, Pamela L, Sharma Pawana, Royle Pamela L, Clar, Christine, Clar, C., Waugh, Norman R, Waugh Norman R, Pamela L Royle, Shyangdan Deepson S, Clar Christine, Waugh, Norman, Norman R Waugh, Sharma, Pawana, Shyangdan, D. (Deepson), Shyangdan, Deepson S, Royle, Pamela   +18 more
core   +2 more sources

EVIDENCE OF THE INFLUENCE OF GLUCAGON-LIKE PEPTIDE ANALOGS IN INFLAMMATORY BOWEL DISEASE: A SCOPING REVIEW [PDF]

Arquivos de Gastroenterologia
Background: Inflammatory bowel disease is a chronic, immune-mediated condition characterized by relapsing intestinal inflammation and progressive tissue damage.
Lucas Dalvi Armond REZENDE, Camila ADOUR, Gabriel Confalonieri BERTOLDI, Marco Antônio Oliveira BRITO, Flávia Lúcia CONCEIÇÃO, Mariana Poltronieri PACHECO   +5 more
doaj   +2 more sources

Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion [PDF]

, 2010
Context: Glucagon-like peptide-1 (GLP-1) is produced by specialized cells in the gut and secreted in response to carbohydrates and lipids. The mechanisms regulating fat-stimulated GLP-1 release have, however, not been clarified in detail.
Schirra, Joerg, D'Amato, Massimo, Göke, Burkhard, Drewe, Juergen, Beglinger, Svetlana, Beglinger, Christoph   +5 more
core   +1 more source

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes [PDF]

Annals of Pediatric Endocrinology & Metabolism, 2017
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary ...
Seungah Lee, Dong Yun Lee
doaj   +1 more source